Saltar al contenido
Merck

Induction of BAG2 protein during proteasome inhibitor-induced apoptosis in thyroid carcinoma cells.

British journal of pharmacology (2008-07-29)
H-Q Wang, H-Y Zhang, F-J Hao, X Meng, Y Guan, Z-X Du
RESUMEN

Proteasome inhibitors exhibit cytotoxic against tumours of different histology. However, the mechanism of apoptosis induction by these compounds remains unclear and is likely to be a complex cascade of events. Bcl-2-associated athanogene (BAG) family proteins are characterized by their property of interaction with a variety of partners involved in modulating the proliferation/death balance, including heat shock proteins (HSP), Bcl-2, Raf-1. The role of BAG family proteins in proteasome inhibition has not been elucidated. Effects of proteasome inhibitors on BAG2 expression were evaluated using real-time reverse transcription-polymerase chain reaction (RT-PCR). BAG2 expression was knocked down by small interfering RNAs (siRNA). Cell death was evaluated using Annexin V/propidium iodide staining and subsequent FACS. The proteasome inhibitors, MG132, PSI, lactacystin and epoxomicin, induced BAG2 at the transcriptional level. MG132-induced apoptosis was significantly suppressed by BAG2 knockdown using RNA interference. Our results suggest that BAG2 is a novel molecule induced by proteasome inhibition, which exhibits a pro-apoptotic property in death of thyroid cancer cells induced by proteasome inhibition.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Cicloheximida, from microbial, ≥94% (TLC)
Sigma-Aldrich
Yoduro de propidio, ≥94.0% (HPLC)
Sigma-Aldrich
Cycloheximide, ≥90% (HPLC)
Sigma-Aldrich
Cicloheximida, Biotechnology Performance Certified
Sigma-Aldrich
Yoduro de propidio, ≥94% (HPLC)
Supelco
Cicloheximida, PESTANAL®, analytical standard